Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

This research study is looking into a new medicine, dazukibart, for people with muscle conditions called dermatomyositis (DM) and polymyositis (PM). These conditions cause muscles to become weak and can also cause a skin rash in DM. The study aims to understand how this new medicine works, if it can help improve symptoms, and if it is safe. Participants in the study will either receive the new medicine or a dummy medicine (placebo) through an IV drip once a month for about a year. By comparing these two groups, researchers hope to learn if dazukibart could be a helpful treatment option.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Pfizer
Einschreibeziel
318
Starten
20 May 2023
Geschätzte Fertigstellung
29 Jul 2030

Worum geht es in dieser Studie?

This study is investigating a new medicine called dazukibart for conditions known as idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM). These are rare conditions where your body's immune system mistakenly attacks your muscles, making them weak. This can make everyday activities like walking, climbing stairs, or getting up from a chair difficult. People with dermatomyositis also often get a distinctive skin rash.

The main goal of this study is to find out if dazukibart can help improve the muscle weakness and other symptoms of DM and PM, and importantly, if it is safe for people to use. To do this, researchers will give some participants the new medicine and others a 'placebo', which looks exactly like the study medicine but contains no active drug. This allows them to clearly see if any changes are due to the new medicine itself.

Understanding how dazukibart works could potentially lead to a new treatment option for people living with these challenging conditions. Your participation could help advance medical knowledge and potentially benefit others in the future.

Wichtige Erkenntnisse

  • This study evaluates a new medicine (dazukibart) for dermatomyositis (DM) and polymyositis (PM).
  • It aims to understand if dazukibart is safe and effective for muscle weakness.
  • Participants will receive either dazukibart or a placebo via IV drip once a month.
  • The study lasts about 13 months and involves regular clinic visits.
  • Participation includes health checks and close monitoring by the study team.

Wer könnte berechtigt sein?

To be considered for this study, you need to be an adult, aged 18 or over, and have been diagnosed with active dermatomyositis (DM) or polymyositis (PM). You should also be taking a steady dose of a common anti-inflammatory medicine (like a corticosteroid) or another type of medicine that calms your immune system, or both.

There are also some reasons why you might not be able to join. For example, if your muscle weakness is due to a different condition, or if you have certain other serious health issues like some cancers, severe infections, or other significant diseases that could make the study medicine unsafe for you. We also can't include people who have had certain organ transplants or serious heart or brain conditions recently.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have active dermatomyositis (DM) or polymyositis (PM)?
  3. Are you currently on a stable dose of certain anti-inflammatory or immune-calming medicines?
  4. Do you have any other serious health conditions like recent cancer, severe infections, or major heart/brain problems?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, it will last for about 13 months. During this time, you will have 15 visits to the study centre. At these visits, you will receive either the study medicine (dazukibart) or a placebo (a dummy medicine with no active ingredients). Both will be given through a drip into your vein (an IV infusion), which takes about an hour, and this will happen every four weeks for 48 weeks.

Throughout the study, the research team will regularly check your health, symptoms, and how you are responding to the treatment. This will involve physical exams, blood tests, and asking questions about how you are feeling. All these checks are done to monitor your safety and see how the medicine is working.

Potenzielle Risiken und Vorteile

Taking part in a study like this might offer potential benefits, such as receiving a new medicine that could help your condition or getting extra medical attention. However, there are also potential risks, as dazukibart is an experimental medicine, and we don't yet know all of its side effects. You might experience discomfort from injections or other procedures, or the medicine might not help your condition. It's important to remember that you can stop taking part in the study at any time, for any reason, without it affecting your usual medical care.

Locations (138)

  • Arizona Arthritis & Rheumatology Research, PLLC
    Verifizierte Postleitzahl
    Glendale, Vereinigte Staaten· Rekrutierung
  • Neuromuscular Research Center
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten· Rekrutierung
  • Mayo Clinic Hospital
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten· Rekrutierung
  • Mayo Clinic in Arizona - Scottsdale
    Verifizierte Postleitzahl
    Scottsdale, Vereinigte Staaten· Rekrutierung
  • 200 UCLA Medical Plaza
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • UCLA Clinical & Translational Research Center (CTRC)
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • UCLA
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • Center for Clinical Research - Chapman Pavilion
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
  • UCI Douglas Hospital
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
  • UCI Health Center for Innovative Health Therapies
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
  • University of California - Irvine
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
  • Samir Macwan, M.D., Inc.
    Verifizierte Postleitzahl
    Rancho Mirage, United States· Rekrutierung

Häufige Fragen

What are dermatomyositis (DM) and polymyositis (PM)?

They are rare conditions where your immune system attacks your muscles, causing weakness and sometimes a skin rash (in DM).

Was ist ein 'Placebo'?

A placebo looks exactly like the study medicine but doesn't contain any active drug. It helps researchers see if the real medicine is effective.

Wie wird das Medikament verabreicht?

The medicine or placebo will be given through a drip into a vein (an IV infusion) at the study centre.

How long will I take part in the study?

You will be in the study for about 13 months, with visits to the study centre every four weeks.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes, you can leave the study at any time you wish, without giving a reason.

Wie Sie mehr erfahren können

Pfizer CT.gov Call Center

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study to Understand How the Study Medicine (PF-06823859) W… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.